In contrast, we observed KRAS mutations to be enriched in B7-H3–high ovarian serous carcinomas (9.8% vs. 6.0%, q < 0.05) as well as MSS colorectal cancers (54.4% vs. 47.4%, q < 0.0001). This evidence concerns the gene KRAS and ovarian serous carcinoma.